Healthcare Industry News: pulse oximeter
News Release - September 4, 2014
Yale-New Haven Hospital Upgrades to Masimo SET(R) Pulse Oximetry for Improved Patient OutcomesNEW HAVEN, CT and IRVINE, CA--(Healthcare Sales & Marketing Network) - Masimo (NASDAQ: MASI) today announced that Yale-New Haven Hospital -- a nonprofit, 1,541-bed tertiary medical center ranked among the best in the U.S. -- has upgraded system-wide to Masimo SET® pulse oximetry, the standard-of-care at leading hospitals around the world.
Yale-New Haven Hospital joins a growing and distinguished global roster of health organizations using Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, clinically shown to virtually eliminate false alarms1 and help clinicians detect life-threatening events.2 Yale-New Haven Hospital's standardization to Masimo SET® pulse oximetry is in keeping with the healthcare organization's dedication to excellence in care and delivering the best possible results for its patients.
"Masimo's SET pulse oximetry technology reduces the measurement error found in other types of pulse oximeters, and in particular offers greater accuracy during states of patient low perfusion -- an important consideration when patients are under anesthesia," said Dr. Douglas Vaughn, M.D., Senior Director of Anesthesia Operations and Medical Director of Perioperative Services at Yale-New Haven Hospital. "We've found SET pulse oximetry to be a valuable tool, both in the operating room and in the intensive care environment."
In addition, a recently published study in the Journal of Perinatology showed that after the neonatal intensive care unit (NICU) at Yale-New Haven Children's Hospital switched to Masimo SET® pulse oximetry, there was a 37% lower rate of severe retinopathy of prematurity (ROP), an eye disorder that can cause blindness in premature babies, and a 53% lower rate of ROP requiring surgery.3
Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry technology has been proven by more than 100 independent and objective studies and used on more than 100 million patients a year in leading hospitals worldwide, including the top 10 on the U.S. News & World Report Best Hospitals Honor Roll (2014-2015). Masimo SET® significantly reduces false alarms (specificity), accurately detects true alarms (sensitivity), and provides measurements when other pulse oximeters fail.1,2 Most importantly, Masimo SET® pulse oximetry has been clinically proven to improve patient outcomes and reduce cost of care by helping clinicians:
- Decrease retinopathy of prematurity (ROP) in neonates by avoiding giving too much oxygen based on inaccurate SpO2 measurements3,4
- Increase detection of critical congenital heart disease (CCHD) in newborns by accurately identifying low SpO2 measurements5,6
- Reduce ventilator weaning time by titrating FiO2 faster and reduce arterial blood gas measurements in the ICU through more reliable SpO2 measurements7 and
- Decrease rapid response activations and ICU transfers to save lives and costs in post-surgical patients on the medical-surgical floors through earlier identification of patients in distress through low SpO2 and abnormal pulse rate measurements.2,8
1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation pulse oximeters during Motion and Low Perfusion in Volunteers" .J Clin Anesth. 2012 Aug;24(5):385-91.
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
3 Bizzarro MJ, Li FY, Katz K, Shabanova V, Ehrenkranz RA, Bhandari V. Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit. Journal of Perinatology (2014) 34, 33-38; doi:10.1038/jp.2013.122; published online 26 September 2013
4 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
5 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
6 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.
7 Durbin, et al. Critical Care Medicine. 2002 Aug.;30(8): 1735 to 1740.
8 Anesthesia Patient Safety Foundation. APSF Newsletter. "No Patient Shall be Harmed by Opioid-Induced Respiratory Depression." 2011; 26(2):21-40. Available online here.
About Yale-New Haven Hospital
Yale-New Haven Hospital is a nationally recognized, 1,541-bed, not-for-profit hospital serving as the primary teaching hospital for the Yale School of Medicine. Yale-New Haven was founded as the fourth voluntary hospital in the U.S. in 1826. Today, the hospital's two New Haven-based inpatient campuses include Yale-New Haven Children's Hospital, Yale-New Haven Psychiatric Hospital and Smilow Cancer Hospital. YNHH has a combined medical staff of about 4,500 university and community physicians practicing in more than 100 specialties. YNHH's York Street campus and associated ambulatory sites are Magnet-designated by the American Nurses Credentialing Center.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET® provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our assumptions regarding the repeatability of clinical results; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.